FDA 483 - Bioreliance Corporation - November 22, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Bioreliance Corporation in Rockville, MD, a control testing laboratory, was cited for two observations during an FDA inspection. The firm failed to thoroughly review unexplained discrepancies and out-of-specification results, lacking scientific justification for retesting and assigning root causes. Additionally, the firm's practice of retesting OOS samples based on client memoranda lacked documentation for qualified dilutions and justification for changes in dilution factors.
ID · 0a91692f-a886-49cb-a834-736dbccf3145